A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

January 12, 2024

Study Completion Date

January 12, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

LY3532226

Administered SC.

DRUG

Placebo

Administered SC.

DRUG

Dulaglutide

Administered SC.

Trial Locations (1)

Profil Institut für Stoffwechselforschung, Neuss

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY